Bcl-2 expression in male breast carcinoma

Virchows Archiv

Volumn 433, Issue 3, 1998, Pages 229-235

  Pich, Achille ^a   Margaria, Elena ^b   Chiusa, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Bcl 2 protein expression; Male breast carcinoma; Prognosis

Indexed keywords

DNA; ESTROGEN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME NOR; CLINICAL ARTICLE; CLINICAL FEATURE; DNA CONTENT; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MALE BREAST; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; DNA, NEOPLASM; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MITOTIC INDEX; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031719878     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050241     Document Type: Article

References (47)

1. Alsabeh R, Wilson CS, Ahn CW, Vasef MA, Battifora H (1996) Expression of bcl-2 protein by breast cancer: a possible diagnostic application. Mod Pathol 9:439-444
2. Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Dalla Palma P, Harris A (1996) Bcl-2 and p53 expression in node-negative breast carcinoma. A study with long-term follow-up. Hum Pathol 27:1149-1155
3. Bhargava V, Kell DL, Van de Rijn M, Wamke RA (1994) Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535-540
4. Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W (1995) Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinico-pathological variables. Ann Oncol 6: 1005-1010
5. Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359-377
6. Bronner MP, Culin C, Reed JC, Furth EE (1995) The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 146:20-26
7. Chhieng DC, Ross JS, Ambros RA (1996) Bcl-2 expression and the development of endometrial carcinoma. Mod Pathol 9:402-406
8. Cox DR (1972) Regression models and life tables (with discussion). J R Stat [B] 34:187-220
9. Crocker J, Boldy DAR, Egan MJ (1989) How should we count AgNORs? Proposals for a standardised approach. J Pathol (Lond) 158:185-188
10. Dixon WJ, Brown MG, Engelman L, Hill MA, Jennrich RI (eds) (1990) BMPD statistical software manual. University of California Press, Berkeley
11. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G (1994) The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 424:47-51
12. Friedrich K, Dimmer V, Haroske G, Lossnitzer A, Kasper M, Theissig F, Kunze KD (1995) Expression of p53 and bcl-2 in correlation to clinicopathological parameters, hormone receptor status and DNA ploidy in breast cancers. Pathol Res Pract 191:1114-1121
13. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA (1983) Method for analysis of cellular DNA content of paraffin-embedded pathologic material using flow cytometry. J Histochem Cytochem 31:1333-1335
14. Hellemans P, Van Dam PA, Weyler J, Van Oosterom AT, Buytaert P, Van Marck E (1995) Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72:354-360
15. Henriksen R, Wilander H, Oberg K (1995) Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 72:1324-1329
16. Hermanek P, Sobin LH (1992) TNM classification of malignant tumours, 4th edn. Springer, New York Berlin Heidelberg
17. Hiort O, Kwan PWL, DeLellis RA (1998) Immunohistochemistry of estrogen receptor protein in paraffin sections. Am J Clin Pathol 90:559-563
18. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336
19. Hurlimann J, Larrinaga B, Vala DL (1995) Bcl-2 protein in invasive breast carcinomas. Virchows Arch 426:163-168
20. Isola J, Visakorpi T, Holli K, Kallioniemi OP (1992) Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114
21. Jensen V, Høyer M, Sørensen FB, Keller J, Jensen OM (1996) MIB-1 expression and iododeoxyuridine labelling in soft tissue sarcomas: an immunohistochemical study including correlations with p53, bcl-2 and histological characteristics. Histopathology 28:437-444
22. Joensuu H, Klemi PJ (1988) Comparison of nuclear DNA content in primary and metastatic differentiated thyroid carcinoma. Am J Clin Pathol 89:35-40
23. Joensuu H, Pylkkanen L, Toikkanen S (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191-1198
24. Kaplan EL, Meier P (1958) Non parametric estimation for incomplete observations. J Am Stat Assoc 53:457-481
25. Kapucuoglu N, Losi L, Eusebi V (1997) Immunohistochemical localisation of Bcl-2 and Bax proteins in in situ and invasive breast carcinomas. Virchows Arch 430:17-22
26. Kardas I, Seitz G, Limon J, Niezabitowski A, Rys J, Theisinger B, Welter C, Blin N (1993) Retrospective analysis of prognostic significance of the estrogen-inducible pS2 gene in male breast carcinoma. Cancer 72:1652-1656
27. Korsmeyer SJ (1992) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80:879-886
28. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL (1994) Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69: 135-139
29. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML (1992) Expression of the protoncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
30. Millis RR (1980) Correlation of hormone receptors with pathological features in human breast cancer. Cancer 46: 2869-2871
31. Oshima K, Kikuchi M, Kobari S, Eguchi F, Masuda Y, Mohtai H, Kimura N, Takeshita M (1991) Bcl-2 gene and prognosis of B-cell lymphoma. Leuk Lymphoma 5:305-310
32. Pezzella E, Turley H, Kuzu I, Tungekur ME, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY (1993) Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690-694
33. Pich A, Pisani P, Krengli M, Cappello N, Navone R (1991) Argyrophilic nucleolar organizer region counts and prognosis in pharyngeal carcinoma. Br J Cancer 64:327-332
34. Pich A, Margaria E.,Chiusa L (1994) Proliferative activity is a significant prognostic factor in male breast carcinoma. Am J Pathol 145:481-489
35. Pich A, Margaria E, Chiusa L, Ponti R, Geuna M (1996) DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma. Hum Pathol 27: 676-682
36. Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R (1994) Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol (Lond) 172: 337-342
37. Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F, Adnet JJ (1986) Improvement in the staining and in the visualisation of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J 18:5-14
38. Rogers S, Day CA, Fox SB (1993) Expression of cathepsin D and estrogen receptor in male breast carcinoma. Hum Pathol 24:148-151
39. Scarff RW, Torloni H (1968) Histological typing of breast tumours. (International histological classification of tumours, no 2). World Health Organization, Geneva
40. Sierra A, Lloveras B, Castellsagué X, Moreno L, Garcia-Ramirez M, Fabra A (1995) Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 60:54-60
41. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U (1994) The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504
42. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B (1996) p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14:1604-1610
43. Teixeira C, Reed JC, Pratt MA (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902-3907
44. Van Sloten HJ, Clahsen PC, Van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, Van De Velde CJ, Van De Vijver MJ (1996) Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 74:78-85
45. Visscher DW, Sarkar F, Tabaczka P, Crissman J (1996) Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma. Mod Pathol 9:642-646
46. Weber-Chappuis K, Bieri-Burger S, Hurlimann J (1996) Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer 32:1686-1692
47. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken M, Frizzera G (1989) Bcl-2 and other genomic alteration in the prognosis of large-cell lymphoma. N Engl J Med 320: 1047-1054